Continued treatment with the anti-interleukin (IL)-23 monoclonal antibody guselkumab generated high efficacy response rates in patients with moderate-to-severe plaque psoriasis, according to findings from the ongoing phase III VOYAGE 2* trial presented at the 2018 American Academy of Dermatology Annual Meeting (AAD 2018) held in San Diego, California, US.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
The humanized IgG1 monoclonal antibody risankizumab cleared plaque psoriasis better than ustekinumab and placebo in two phase III head-to-head studies. Risankizumab also appeared to be superior to ustekinumab or placebo in many endpoints.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
It takes just less than 4 days for COVID-19 to spread from one person to another and cause symptoms, and more than 10 percent of the cases are infected by a person who has caught the virus but yet to show symptoms, recent studies suggest.